16 May 2024
Scancell Holdings plc
("Scancell" or the
"Company")
Scancell
to present at the Sachs 10th Annual
Oncology Innovation Forum
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer
and infectious disease, is pleased to announce that its Chief
Financial Officer, Sath Nirmalananthan, will be presenting, and
taking part in a panel discussion, at the Sachs 10th Annual
Oncology Innovation Forum taking place on the 31st May
2024, at the beginning of the ASCO meeting.
Sath will be participating in the
"Advanced Immunotherapies Panel: Cell Therapies & Cancer
Vaccines", alongside other companies including AstraZeneca, BTIG
and Lumanity. The panel will discuss the current and future role of
cell therapies and cancer vaccines and take place from 11:40am -
12:30pm CDT.
Sath has also been invited to give a
company presentation, taking place from 1:20pm - 1:40pm CDT at
Track B, Sinclair Ballroom, where he will
discuss the ongoing Phase 2 SCOPE trial, investigating its cancer
vaccine, SCIB1, in combination with checkpoint inhibitors (CPIs) in
advanced melanoma and early data from the ongoing Phase 1/2 ModiFY
trial with patients receiving Modi-1 as a monotherapy in a range of
hard-to-treat solid tumours, which has shown good T cell responses,
safety and tolerability.
Sath Nirmalananthan, Chief Financial Officer and Director of
Scancell, said: "I am pleased to be
invited to participate in both the panel discussion and to present
details from our ongoing Phase 2 SCOPE trial and MofiFy study at
this esteemed Forum. The program is focused on the latest
innovation in IO targets and modalities, and I am also looking
forward to highlighting the potential of our proprietary antibody
technology platform and our innovative cancer vaccines, and to
showcase the great work Scancell is making in this
field."
If you would like to arrange a
meeting at the Forum, please contact commercial.enquiries@scancell.co.uk.
-ENDS-
|
For further
information, please contact:
|
|
|
Scancell
Holdings plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Stifel Nicolaus
Europe Limited (Nominated Adviser and Joint Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira Essebiyea (Healthcare Investment
Banking)
|
|
|
Nick Harland (Corporate Broking)
|
|
|
WG Partners LLP
(Joint Broker)
|
+44 (0) 20 3705 9330
|
|
David Wilson/Claes Spang/Sathesh
Nadarajah/Erland Sternby
|
|
|
Panmure Gordon (UK)
Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate Finance)
|
|
|
Rupert Dearden (Corporate Broking)
|
|
About
Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer and infectious disease. The Company is
building a pipeline of innovative products by utilising its four
technology platforms: Moditope®
and ImmunoBody®
for vaccines and GlyMab® and
AvidiMab® for
antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab®) or
enhances the potency of antibodies and their ability to directly
kill tumour cells
(AvidiMab®).
For further information about Scancell, please
visit: https://www.scancell.co.uk/